Subjects: Opioid-Related Disorders -- drug therapy / Copyright: Public domain - Digital Collections - National Library of Medicine Search Results

Start Over Subjects Opioid-Related Disorders -- drug therapy ✖ Copyright Public domain ✖

11. Opioid use disorder: developing depot buprenorphine products for treatment

Publication:: Silver Spring, MD : Center for Drug Evaluation and Research, February 2019
Subject(s):: Buprenorphine -- therapeutic use
Drug Development
Opioid-Related Disorders -- drug therapy
Buprenorphine -- administration & dosage
Clinical Trials as Topic
Delayed-Action Preparations
Narcotic Antagonists
Opiate Substitution Treatment
Humans
United States
United States. Department of Health and Human Services.
United States. Food and Drug Administration.

12. Opioid use decreased in Medicare Part D, while medication-assisted treatment increased

Publication:: [Washington, D.C.] : U.S. Department of Health and Human Services, Office of Inspector General, July 2019
Subject(s):: Analgesics, Opioid -- therapeutic use
Medicare Part D
Opiate Substitution Treatment
Opioid-Related Disorders -- drug therapy
Drug Overdose -- drug therapy
Drug Utilization -- trends
Forecasting
Inappropriate Prescribing
Naloxone -- therapeutic use
State Government
Humans
United States

13. The risk of misuse and diversion of buprenorphine for opioid use disorder appears to be low in Medicare Part D

Publication:: Washington, D.C. : U.S. Department of Health and Human Services, Office of Inspector General, May 2023
Subject(s):: Buprenorphine
Buprenorphine, Naloxone Drug Combination
Government Regulation
Medicare Part D
Opioid-Related Disorders -- drug therapy
United States

14. Many Medicaid enrollees with opioid use disorder were treated with medication: however, disparities present concerns

Publication:: Washington, D.C. : U.S. Department of Health and Human Services, Office of Inspector General, September 2023
Subject(s):: Ethnic and Racial Minorities -- statistics & numerical data
Government Regulation
Health Inequities
Healthcare Disparities
Medicaid
Morphinans -- supply & distribution
Opiate Substitution Treatment
Opioid-Related Disorders -- drug therapy
United States

15. The risk of misuse and diversion of buprenorphine for opioid use disorder in Medicare Part D continues to appear low: 2022

Publication:: [Washington, D.C.] : U.S. Department of Health and Human Services, Office of Inspector General, November 2023
Subject(s):: Buprenorphine
Drug Users -- statistics & numerical data
Government Regulation
Medicare Part D -- economics
Opiate Substitution Treatment
Opioid-Related Disorders -- drug therapy
Prescription Drug Diversion -- statistics & numerical data
United States

16. The consistently low percentage of Medicare enrollees receiving medication to treat their opioid use disorder remains a concern

Publication:: Washington, D.C. : U.S. Department of Health and Human Services, Office of Inspector General, December 2023
Subject(s):: Government Regulation
Medicare
Opiate Overdose -- prevention & control
Opiate Substitution Treatment
Opioid-Related Disorders -- drug therapy
United States

17. The opium habit: its successful treatment by the Avena sativa, a paper read before the New York State Medical Society, February 9, 1882

Author(s):: Sell, E. H. M. (Edward Herman Miller), 1832-1920, author
Publication:: Jersey City : Evening Journal Print, 1882
Subject(s):: Opioid-Related Disorders -- drug therapy
Avena
Plant Extracts -- therapeutic use